KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. PMID 39801286 · Mod Rheumatol · 2025-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials. PMID 39657989 · Mod Rheumatol · 2025-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4. PMID 39506562 · Mod Rheumatol · 2025-Apr-08 The record describes a randomized, Phase 3 trial of a drug (filgotinib) in humans, but the disease is rheumatoid arthritis, which is not oncology. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (it reports safety and clinical remission).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. PMID 40197415 · AIDS Res Ther · 2025-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, on quality of life in patients with pancreatic cancer: a randomised controlled trial protocol. PMID 40197383 · Nutr J · 2025-Apr-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial. PMID 40197313 · BMC Cancer · 2025-Apr-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Digital Health Intervention to Reduce Malnutrition Among Individuals With Gastrointestinal Cancer Receiving Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy: Feasibility, Acceptability, and Usability Trial. PMID 40194318 · JMIR Cancer · 2025-Apr-07 This is a single-arm feasibility study of a digital health intervention for malnutrition in GI cancer patients, not a randomized Phase III trial with a drug intervention and a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. PMID 39815637 · Jpn J Clin Oncol · 2025-Apr-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113. PMID 39775866 · Jpn J Clin Oncol · 2025-Apr-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. PMID 40333248 · Vaccines (Basel) · 2025-Apr-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Support for young people who are distressed by hearing voices: protocol for an uncontrolled feasibility evaluation of a psychological intervention package delivered within secondary schools (the ECHOES study). PMID 40186222 · Pilot Feasibility Stud · 2025-Apr-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 40186126 · BMC Cancer · 2025-Apr-04 The publication is a clinical trial protocol for a Phase III randomized trial comparing a drug (177Lu-edotreotide) to another drug (everolimus) with a primary time-to-event efficacy endpoint (PFS). However, it does not contain results; it is a protocol description. Therefore, it is not an original formal-result report and is excluded.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. PMID 40168091 · J Crohns Colitis · 2025-Apr-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. PMID 40333267 · Vaccines (Basel) · 2025-Apr-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of RSV Prevention in Infancy on Prevalence of Asthma Among 9-14-Year-old Native American Children in the Southwest United States. PMID 40208934 · Pediatr Infect Dis J · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours. PMID 40174223 · N Engl J Med · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. PMID 39602624 · N Engl J Med · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Gain-Framed Text Messages and Nicotine Replacement Therapy for Smoking Cessation Among Lung Cancer Screening Patients: A Brief Report of a Pilot Randomized Controlled Trial. PMID 40283767 · Int J Environ Res Public Health · 2025-Apr-02 The study is an oncology randomized controlled trial but is a pilot study (not Phase III or definitive) and the intervention (smoking cessation with NRT) is not a drug treatment for the malignancy itself; it lacks a primary time-to-event efficacy endpoint for cancer.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Wise or wide (WoW) study protocol: a national, multicentre, prospective, randomised and controlled, parallel group, non-inferiority study to compare single-staged versus two-staged excisions of thin invasive (≤1.0 mm) melanoma. PMID 40180392 · BMJ Open · 2025-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis. PMID 40180374 · BMJ Open · 2025-Apr-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Feasibility of an exercise program in endocrine-treated metastatic breast cancer patients with overweight: protocol for the FEMA study. PMID 40176194 · Pilot Feasibility Stud · 2025-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma. PMID 40788733 · Indian J Cancer · 2025-Apr-01 The study meets most eligibility criteria: it is an oncology, human, randomized trial with drug intervention, time-to-event (PFS) analysis, and original results. However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the available metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, leading to ineligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective comparative study of pre-op chemoradiotherapy followed by surgery versus upfront surgery followed by adjuvant chemoradiotherapy in locally advanced borderline resectable oral cavity cancer. PMID 40616538 · J Cancer Res Ther · 2025-Apr-01 The study is a randomized trial in oncology with a drug intervention, but the provided metadata does not confirm it as a Phase III or Phase II/III trial. Furthermore, the reported primary endpoints are pathological and surgical outcomes, not a time-to-event efficacy endpoint like OS or DFS, which are required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions. PMID 40333232 · Vaccines (Basel) · 2025-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial. PMID 40257799 · JAMA Netw Open · 2025-Apr-01 The study is a randomized trial in human oncology with a drug intervention (clinical trials as the intervention), but it lacks a time-to-event efficacy endpoint and does not explicitly test a drug intervention in the arms. The primary outcome is trial enrollment rate, not OS/PFS/DFS/EFS/RFS/TTP or any other time-to-event measure. No Kaplan-Meier curves or hazard ratios are reported. The study is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with time-to-event endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer. PMID 40106307 · Cancer · 2025-Apr-01 The record describes a secondary subgroup analysis of individual participant-level data from the TITAN trial, investigating heterogeneous treatment effects based on tumor burden. While it analyzes data from a Phase III randomized trial with drug intervention and time-to-event endpoints, it is not the original formal-result report of the trial's primary efficacy analysis. It is a post-hoc or subgroup analysis focused on effect modification, not the primary or key secondary result report of the trial itself.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. PMID 40048197 · JAMA Ophthalmol · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. PMID 40048178 · JAMA Ophthalmol · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lung Cancer Surveillance for Patients With Head and Neck Cancer. PMID 40048159 · JAMA Otolaryngol Head Neck Surg · 2025-Apr-01 The record is for a randomized trial in head and neck cancer with overall survival and disease-free survival as secondary outcomes, but it does not involve a drug-containing intervention (comparing imaging modalities). The trial phase is not explicitly stated in the provided metadata, so it cannot be confirmed as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer. PMID 40015915 · J Nucl Med · 2025-Apr-01 The report is a secondary analysis of FDG-PET parameters as prognostic factors from within a phase II/III randomized trial. While the trial itself is randomized and phase III with time-to-event endpoints, the specific analysis presented lacks evidence of a drug-containing intervention (it compares radiotherapy dose strategies) and is not the primary efficacy report of the trial.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis. PMID 39992106 · Int J Surg · 2025-Apr-01 The record is from a Phase III randomized trial with time-to-event endpoints, but the intervention is purely surgical (lymphadenectomy). There is no drug-containing intervention, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. PMID 39946142 · JAMA Oncol · 2025-Apr-01 The record is a subgroup/biomarker analysis of a randomized trial with drug intervention and time-to-event endpoints, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the primary focus is on TILs subgroup effects, not the overall trial primary efficacy result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for nonmuscle-invasive bladder tumor. PMID 39927777 · Int J Surg · 2025-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial. PMID 39918552 · Clin Cancer Res · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial. PMID 39913118 · JAMA Oncol · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort. PMID 39908003 · Clin Cancer Res · 2025-Apr-01 The study meets criteria for oncology, human, randomized, original report with time-to-event analysis. However, it is excluded because the intervention is non-drug-only (radiotherapy), lacking a drug-containing intervention as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. PMID 39814441 · J Rheumatol · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bioequivalence of Preservative-Free and Preserved Omidenepag Isopropyl 0.002% Ophthalmic Solutions in Patients With Primary Open Angle Glaucoma or Ocular Hypertension: Phase 3 DAISY Study. PMID 39750078 · J Glaucoma · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. PMID 39739622 · Int J Cancer · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial. PMID 39686540 · Int J Cancer · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. PMID 39676239 · J Acquir Immune Defic Syndr · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results. PMID 39668671 · Melanoma Res · 2025-Apr-01 The record is a systematic scoping review of PRO reporting in trials, not an original trial report with primary/key secondary time-to-event efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Recurrent Pancreatic Cancer. PMID 39626189 · Pancreas · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. PMID 39615657 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 The study is a randomized, human, oncology trial reporting time-to-event efficacy endpoints (PFS, OS). However, it is excluded because the intervention does not include a drug-containing arm (both arms receive identical temozolomide; the comparison is of radiation guidelines, not a drug) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR. PMID 39612953 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. PMID 39455063 · J Am Soc Nephrol · 2025-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. PMID 39331638 · Rheumatology (Oxford) · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluating Equity in Clinical Trial Accessibility: An Analysis of Demographic, Socioeconomic, and Educational Disparities in Irritable Bowel Syndrome Drug Trials. PMID 39315667 · Am J Gastroenterol · 2025-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. PMID 39250515 · Hepatology · 2025-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Laparoscopic Pylorus-preserving Gastrectomy Versus Distal Gastrectomy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial (KLASS-04). PMID 39219553 · Ann Surg · 2025-Apr-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -